AKT1 and Miyoshi myopathy: Liu et al. reported that miR-215-5p acted as an anticancer factor in MM via targeting RUNX1 and blocking the PI3K/AKT/mTOR pathway (Liu et al. 2019b) and miR-186 was shown to suppress cell proliferation in MM (Deng et al. 2019).